AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
But Humira remains the one to beat.
ACC 2023 – Merck’s oral cholesterol lowerer shows mid-stage promise
The oral PCSK9 project MK-0616 meets its targets in phase 2, which could be bad news for Novartis.
Spotlight – What's next in Nash
The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.
Go or no go? Vaccines and neurology up for discussion
FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.
US deal watchdog's bark could be worse than its bite
Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?
Spotlight – still plenty of hopefuls in lung fibrosis
Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.
